|
Patent landscape, scope, and claims summary: |
Analysis of United States Patent 7,951,557
United States Patent 7,951,557, titled "Formulations of kinase inhibitors," was granted on May 31, 2011, to Intellikine, Inc. The patent claims specific crystalline forms of certain PI3K inhibitors, notably an amorphous form and two crystalline forms designated as Form I and Form II. These formulations are asserted to offer improved stability and bioavailability compared to existing forms. The patent has been extensively litigated, particularly in the context of the drug alpelisib (Piqray).
What are the core claims of US Patent 7,951,557?
The patent's independent claims are directed towards specific solid-state forms of a chemical compound, namely 4-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-N-(2-methyl-6-( (2,2,2-trifluoroethyl)amino)phenyl)benzamide. The patent asserts protection for:
- Claim 1: An amorphous form of the compound.
- Claim 2: A crystalline form of the compound, designated as Form I.
- Claim 3: A crystalline form of the compound, designated as Form II.
- Dependent claims further define these forms through specific characteristics such as X-ray powder diffraction (XRPD) peaks, differential scanning calorimetry (DSC) data, and moisture content. For example, Claim 4 specifies Form I by its XRPD peaks at certain 2-theta angles. Claim 10 defines Form II by its XRPD peaks.
The specification describes methods for preparing these solid forms and highlights their utility in pharmaceutical compositions. The alleged advantages include improved stability, reduced hygroscopicity, and enhanced bioavailability, which are critical for drug development and efficacy.
What is the asserted therapeutic target and compound?
The patent targets the phosphoinositide 3-kinase (PI3K) signaling pathway. The specific compound described and claimed is a potent and selective inhibitor of PI3K. This pathway is implicated in various cellular processes, including cell growth, proliferation, survival, and metabolism. Dysregulation of the PI3K pathway is a common driver in many human cancers. The compound disclosed in the patent is the active pharmaceutical ingredient (API) later developed and marketed as alpelisib, under the brand name Piqray, by Novartis. Alpelisib is specifically a PI3Kα isoform inhibitor.
What are the key solid-state forms claimed?
US Patent 7,951,557 claims three distinct solid-state forms of the PI3K inhibitor:
- Amorphous Form: This form lacks long-range molecular order. Amorphous forms can offer advantages in solubility and dissolution rates but often suffer from poor physical stability and hygroscopicity.
- Form I (Crystalline): This is a specific crystalline polymorph of the compound. Crystalline forms are generally preferred in pharmaceutical development due to their defined structure, stability, and reproducible manufacturing properties. Form I is characterized by specific diffraction patterns and thermal properties as detailed in the patent.
- Form II (Crystalline): This is another distinct crystalline polymorph. Like Form I, it possesses a unique three-dimensional arrangement of molecules. Form II is also defined by its specific XRPD and DSC characteristics, distinguishing it from Form I and the amorphous form.
The patent asserts that these forms, particularly Form I and Form II, are novel and offer significant advantages over other potential solid-state forms, including improved handling, storage stability, and pharmacokinetic profiles.
What are the reported advantages of the claimed forms?
The patent specification and subsequent litigation documents detail several asserted advantages of the claimed amorphous, Form I, and Form II solid-state forms:
- Improved Stability: Crystalline forms are generally more stable than amorphous forms. The patent claims that Form I and Form II exhibit superior chemical and physical stability, meaning they are less prone to degradation and phase transitions during storage and manufacturing.
- Reduced Hygroscopicity: Hygroscopicity refers to a substance's tendency to absorb moisture from the air. High hygroscopicity can lead to instability, caking, and altered dissolution properties. The claimed crystalline forms are described as having lower moisture uptake compared to the amorphous form.
- Enhanced Bioavailability: The patent suggests that these specific solid forms, particularly when formulated appropriately, can lead to improved absorption of the drug into the bloodstream, thus increasing its bioavailability and therapeutic efficacy.
- Manufacturability: Certain crystalline forms can be easier to handle and process during pharmaceutical manufacturing, leading to more consistent product quality and potentially lower manufacturing costs.
These purported advantages are crucial for demonstrating utility and non-obviousness in patent law, as well as for ensuring effective and safe drug delivery in clinical practice.
What is the litigation history surrounding US Patent 7,951,557?
US Patent 7,951,557 has been a subject of significant patent litigation, primarily as it pertains to the drug alpelisib (Piqray). The patent has been asserted against generic manufacturers seeking to market their own versions of alpelisib. Key aspects of the litigation include:
- Infringement Actions: The patent holder, and later Novartis (the marketer of Piqray), has filed infringement lawsuits against companies developing generic alpelisib products. These lawsuits typically allege that the generic drug product utilizes or is made using the patented amorphous, Form I, or Form II solid-state forms.
- Validity Challenges: In response to infringement claims, defendants have frequently challenged the validity of the patent. Common grounds for challenging patent validity include:
- Obviousness: Arguing that the claimed forms would have been obvious to a person skilled in the art at the time of invention, based on existing prior art. This often involves demonstrating that the prior art disclosed similar compounds or polymorphic forms and that the claimed invention did not provide unexpected results.
- Lack of Novelty: Asserting that the claimed forms were already known or publicly disclosed before the patent's filing date.
- Insufficient Disclosure/Enablement: Claiming that the patent does not adequately describe how to make or use the claimed invention.
- Key Cases: Litigation has involved multiple rounds of court proceedings, including district court trials and appeals. These cases often involve extensive expert testimony regarding solid-state chemistry, patent law, and pharmaceutical science.
- Outcomes: The outcomes of these litigations have varied. Some cases have resulted in findings of infringement and validity, while others have seen patents invalidated or found not infringed. The successful defense against patent challenges or successful assertion of infringement can significantly impact the market exclusivity of a drug.
- Focus on Polymorphism: The litigation frequently centers on the intricate details of solid-state chemistry, including the characterization and differentiation of polymorphic forms. Disputes often arise over whether a generic manufacturer's product uses a specifically claimed form or a different, non-infringing form.
The patent's active litigation history underscores its importance in protecting the market for alpelisib and highlights the strategic value of solid-state patent claims in the pharmaceutical industry.
What is the status of the patent and its expiration?
US Patent 7,951,557 has a statutory expiration date. Patents filed after June 8, 1995, generally have a term of 20 years from the filing date. The filing date for US Patent 7,951,557 was December 16, 2008. Therefore, the patent is expected to expire on December 16, 2028, assuming no extensions or adjustments significantly alter this date.
As of the current date, the patent remains in force, though its expiration is approaching. This near-term expiration is a critical factor for generic manufacturers planning market entry and for any company considering licensing or challenging the patent. The ongoing litigation further complicates its effective lifespan and market impact.
What are the implications for generic drug development?
The existence and claims of US Patent 7,951,557 have significant implications for generic drug development targeting alpelisib:
- Freedom-to-Operate (FTO): Generic companies must conduct thorough FTO analyses to ensure their proposed alpelisib product does not infringe any valid and unexpired patents, including US Patent 7,951,557. This requires careful examination of the API's solid-state form and potentially the manufacturing process.
- Polymorph Selection: Generic manufacturers may attempt to develop alpelisib using a solid-state form that is not claimed by US Patent 7,951,557. This involves identifying and characterizing novel polymorphic forms or utilizing the amorphous form if it is not specifically covered or is found invalid.
- Litigation Risk: Developing a generic product that could potentially infringe this patent exposes generic companies to costly and time-consuming litigation. The history of litigation around this patent suggests that the patent holder will actively defend its claims.
- Patent Expiration Strategy: Companies may strategically delay market entry until the expiration of key patents, such as US Patent 7,951,557, to avoid infringement and litigation. However, this also means delaying revenue generation.
- Settlement and Licensing: In some cases, generic manufacturers may seek to settle with the patent holder, which could involve licensing agreements that permit market entry under specific terms, often after the patent's expiration or with a staggered entry.
- Patent Challenges: Generic companies may proactively challenge the validity of the patent in anticipation of or in response to an infringement suit, aiming to clear the path for market entry.
Navigating the patent landscape surrounding US Patent 7,951,557 is a critical step for any generic company aiming to enter the alpelisib market. The specific solid-state forms claimed necessitate a deep understanding of polymorph chemistry and patent law.
What is the competitive landscape for PI3K inhibitors?
The PI3K pathway is a highly validated target in oncology, leading to a competitive landscape for PI3K inhibitors. US Patent 7,951,557 is specific to a particular compound and its solid-state forms, but the broader field includes many other inhibitors targeting various isoforms of PI3K.
- Broad PI3K Inhibitors: Early PI3K inhibitors were pan-PI3K inhibitors, targeting all isoforms. These often faced challenges with toxicity due to the essential roles of certain PI3K isoforms in normal tissues.
- Isoform-Selective Inhibitors: The development has shifted towards isoform-selective inhibitors, which aim to exploit the specific roles of particular PI3K isoforms (e.g., PI3Kα, PI3Kδ, PI3Kβ, PI3Kγ) in different cancers while minimizing off-target toxicities. Alpelisib, the compound associated with US Patent 7,951,557, is a PI3Kα selective inhibitor.
- Approved Therapies: Beyond alpelisib, other PI3K inhibitors have received regulatory approval for various indications. Examples include idelalisib (Zydelig, PI3Kδ selective), duvelisib (Copiktra, PI3Kδ and PI3Kγ selective), and taselisib (used in combination). Each of these drugs has its own patent protection covering the compound, formulations, and methods of use.
- Pipeline Agents: Numerous PI3K inhibitors are in various stages of clinical development, targeting different isoforms and cancer types. This active pipeline indicates continued investment and interest in this class of drugs.
- Combination Therapies: PI3K inhibitors are often investigated in combination with other anti-cancer agents, such as hormonal therapies (as with alpelisib and fulvestrant for HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation) or chemotherapy, to enhance efficacy.
The competitive landscape is characterized by ongoing research into isoform selectivity, new chemical entities, novel formulations, and strategic combination therapies. Patent protection for specific compounds and their advantageous solid forms, like those claimed in US Patent 7,951,557, is a critical element in establishing and defending market position within this dynamic field.
Key Takeaways
- US Patent 7,951,557 protects specific solid-state forms (amorphous, Form I, Form II) of a PI3K inhibitor that is the active ingredient in the drug alpelisib (Piqray).
- The patent claims improved stability, reduced hygroscopicity, and enhanced bioavailability as advantages of the protected forms.
- The patent has been subject to significant litigation, with challenges often focusing on obviousness and infringement related to the specific polymorphic forms.
- The patent is set to expire on December 16, 2028, making its remaining term a critical consideration for generic market entry strategies.
- Generic development of alpelisib requires careful navigation of this patent, including FTO analysis and potential development of non-infringing solid-state forms.
- The PI3K inhibitor field is competitive, with a focus on isoform selectivity and combination therapies, making solid-state patent protection a key strategic asset.
FAQs
-
What specific PI3K isoform does the compound protected by US Patent 7,951,557 inhibit?
The compound is a PI3Kα selective inhibitor.
-
When does US Patent 7,951,557 expire?
The patent is scheduled to expire on December 16, 2028.
-
Can generic manufacturers develop alpelisib using an amorphous form?
US Patent 7,951,557 claims an amorphous form. Generic manufacturers must assess whether their proposed amorphous form infringes this claim, or if the claim is otherwise invalid.
-
What are the main grounds for challenging the validity of US Patent 7,951,557?
Common grounds include obviousness over prior art and lack of novelty.
-
Does the patent cover the manufacturing process of alpelisib, or only its solid-state forms?
The primary claims of US Patent 7,951,557 are directed towards specific solid-state forms (amorphous, Form I, and Form II) of the compound, rather than the manufacturing process itself. However, manufacturing processes that necessarily produce these claimed forms could potentially be seen as infringing.
Citations
[1] Intellikine, Inc. (2011). Formulations of kinase inhibitors. U.S. Patent No. 7,951,557. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
